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short review will briefly highlight some of these diverse approaches to 74 computational kinase discovery presented at the conference. 75 structural clustering of all mammalian kinase X-ray conformations. 85 The structures formed distinct clusters when plotted in 2 specialized 86 graphs, a "DFG-plot" and a "Helix-C plot", according to a few simple geo-87 metric criteria. The secret to getting distinct interpretable clusters was 88 the identification of pseudo DFG torsions formed by sets of 4 consecu-89 tive alpha carbons, a measure of the torsion between two consecutive 90 sidechains. These angles were divided into regions: FG-down/DFG-ac-91 tive/G-down, and DFG-in/out. The structures could then be plotted on 92 the 2 graphs by adding a distance to helix-C, classified as in/dilated/ 93 out. Comparing two subsets of the PDB, prior and post June 2010, 94 gave similar distributions of clusters ( Fig. 1 ). Analyzing the populations 95 provided estimates of the energy differences between kinase conforma-96 tional states. One interesting conclusion was that phosphorylation 97 shifts the relative balance between active and inactive conformation 98 by 1 kcal/mole on average ( Fig. 2 ). This observation can explain why 99 type II inhibitors, which bind in the inactive (DFG-out) conformation, 100 exhibit lower potency (by 10 fold on average), but are measurable in 101 biochemical (phosphorylated) kinase assays. He also observed that 102 first-shell polar residues hinder the DFG transition. The research 103 extends the long standing interest in classification of binding modes of 104 kinase inhibitors [1] .
Discussion

105
Aiming to understand energetic and conformational preferences 106 leading to observed selectivity, Benoit Roux and his co-workers Yen- is more stable in the DGF-in by 5.4 kcal/mol, suggesting that the free 117 energy cost of the DFG flip between these two kinases could be one de-118 terminant of type II selectivity [2] . The team also calculated the affinity 119 of Imatinib to the binding pocket by using the "alchemical double nases for which no experimental type-II structure has been reported.
142
These structures included CDK2.
143
A unique binding mode was reported for the ERK inhibitor 144 SCH772984, which bound in a so far unreported conformation to 145 ERK1 and ERK2 ( Fig. 4 ). In this novel binding mode, which would be im- computational analog modeling to identify strong interactions with 174 MELK (Fig. 5 ). Another approach utilizing the ASTEX structural 175 informatics platform allowed for the rational design of a 19 nM type II Fig. 5 . A low affinity fragment hit was optimized by SBDD to a selective 37 nM tool compound. tested for activity [9] . Three showed activity improvement ranging 193 from 2 to 10-fold from the initial hit. 
based on sequences chosen to represent binding site residues (Fig. 11 ).
250
Statistically, these corresponded quite well with experimental inhibi-251 tion profiles from Ambit 2011 data [16], especially for tyrosine kinase 252 targets (Fig. 12) . Such analyses support the use of surrogate kinases in 253 structure-based drug discovery [17] , and may aid in choosing focused 254 screening libraries for repurposing or retargeting known compounds.
255
At a higher level of information content, similarity analyses of target 256 proteins would involve comparisons of X-ray structures. Currently, Fig. 11 . Disk sizes and colors depict pseudosequence similarities to PKB alpha. 
including [19] ). For well characterized diseases, the data increasingly highlights have whetted your appetite to dig further into some of 304 these topics in the accompanying articles in this issue.
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307 Fig. 13 . Screenshot of Foldit, from the new Rosetta Ligand application, a crowd-sourced multiplayer game adopted for ligand design. A) Hydrogen bond contacts are shown in light-blue/ white lines and B) surface exposed hydrophobic residues are shown as yellow blobs. C) The ligand design panel is the control center for players and allows them to choose from a variety of fragments, bond manipulations, and element modifications to design the ligand in the protein binding pocket. D) When players hover over a fragment, a ghost view of the new fragment is drawn at the attachment point (light blue glowing fragment). E) The ligand viewing option menu allows players to turn off QSAR grids calculated for hydrogen bond acceptors and donors F) (shown as dark blue fog) or repulsion for the ligand, with slider bars on the side to adjust the alpha of the drawn fogs. Players can turn on the protein isosurface or a ligand centric view that draws the isosurface around the ligand, allowing for advance spatial alignment of the ligand in the binding pocket. 
